Integrin alpha4beta1 antagonists - Pipeline Insight, 2024

This “Integrin alpha4beta1 antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Integrin alpha4beta1 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Integrin alpha4beta1 antagonists Understanding

Integrin alpha4beta1 antagonists: Overview

Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins a IIbß3, a4ß7/a4ß1 and aLß2 for cardiovascular diseases, inflammatory bowel disease/multiple sclerosis and dry eye disease, respectively. The related integrins a4ß7 and a4ß1 are therapeutic targets that are expressed on leukocytes and also recognize short peptide sequences, one of which is Leu-Asp-Val (LDV). There is some preclinical evidence that a3ß1 (ref.82), a4ß1 (ref.83) and a8ß1 integrins play a role in pulmonary fibrosis, and that avß8 is important in small airway fibrosis associated with chronic obstructive pulmonary fibrosis andasthma.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Integrin alpha4beta1 antagonists R&D. The therapies under development are focused on novel approaches for Integrin alpha4beta1 antagonists.

Integrin alpha4beta1 antagonists Emerging Drugs Chapters

This segment of the Integrin alpha4beta1 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Integrin alpha4beta1 antagonists Emerging Drugs

Natalizumab: Biogen Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. It Binds to the a4-subunit of a4b 1 and a4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their counter-receptor(s). Currently, it is being evaluated in phase II stage of development to treat Graft-versus-hostdisease.

AXR 159: Axero Vision AXR-159 is being developed for the treatment of chronic Dry eyes disease (DED). AXR-270 is being developed for the short-term treatment of DED. Currently, it is in phase II stage of development totreatDED.

Integrin alpha4beta1 antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Integrin alpha4beta1 antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Integrin alpha4beta1 antagonists

There are approx. 5+ key companies which are developing the Integrin alpha4beta1 antagonists. The companies which have their Integrin alpha4beta1 antagonists drug candidates in the most advanced stage, i.e. Phase II include, Biogen.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Integrin alpha4beta1 antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Integrin alpha4beta1 antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Integrin alpha4beta1 antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Integrin alpha4beta1 antagonists drugs.

Integrin alpha4beta1 antagonists Report Insights

• Integrin alpha4beta1 antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Integrin alpha4beta1 antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Integrin alpha4beta1 antagonists drugs?
• How many Integrin alpha4beta1 antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Integrin alpha4beta1 antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Integrin alpha4beta1 antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Integrin alpha4beta1 antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biogen
• AxeroVision
• Polpharma Biologics
• EA Pharma
• BioMAS
• Feramda

Key Products

• Natalizumab
• AXR-159
• PB-006
• AJM 300
• AS 101
• BIIB 107
• SAS

This product will be delivered within 1-3 business days.